384 related articles for article (PubMed ID: 30166519)
21. A P53-Independent DNA Damage Response Suppresses Oncogenic Proliferation and Genome Instability.
Fagan-Solis KD; Simpson DA; Kumar RJ; Martelotto LG; Mose LE; Rashid NU; Ho AY; Powell SN; Wen YH; Parker JS; Reis-Filho JS; Petrini JHJ; Gupta GP
Cell Rep; 2020 Feb; 30(5):1385-1399.e7. PubMed ID: 32023457
[TBL] [Abstract][Full Text] [Related]
22. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
23. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
[TBL] [Abstract][Full Text] [Related]
24. Cyclin-Dependent Kinase Inhibitor AT7519 as a Potential Drug for MYCN-Dependent Neuroblastoma.
Dolman ME; Poon E; Ebus ME; den Hartog IJ; van Noesel CJ; Jamin Y; Hallsworth A; Robinson SP; Petrie K; Sparidans RW; Kok RJ; Versteeg R; Caron HN; Chesler L; Molenaar JJ
Clin Cancer Res; 2015 Nov; 21(22):5100-9. PubMed ID: 26202950
[TBL] [Abstract][Full Text] [Related]
25. Galectin-3 impairment of MYCN-dependent apoptosis-sensitive phenotype is antagonized by nutlin-3 in neuroblastoma cells.
Veschi V; Petroni M; Cardinali B; Dominici C; Screpanti I; Frati L; Bartolazzi A; Gulino A; Giannini G
PLoS One; 2012; 7(11):e49139. PubMed ID: 23152863
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.
Chesler L; Goldenberg DD; Collins R; Grimmer M; Kim GE; Tihan T; Nguyen K; Yakovenko S; Matthay KK; Weiss WA
Neoplasia; 2008 Nov; 10(11):1268-74. PubMed ID: 18953436
[TBL] [Abstract][Full Text] [Related]
27. Thymidylate synthase inhibitor raltitrexed can induce high levels of DNA damage in MYCN-amplified neuroblastoma cells.
Yamashita K; Kiyonari S; Tsubota S; Kishida S; Sakai R; Kadomatsu K
Cancer Sci; 2020 Jul; 111(7):2431-2439. PubMed ID: 32415892
[TBL] [Abstract][Full Text] [Related]
28. Oncolytic adenovirus-mediated short hairpin RNA targeting MYCN gene induces apoptosis by upregulating RKIP in neuroblastoma.
Li Y; Zhang H; Zhu X; Feng D; Zhang D; Zhuo B; Zheng J
Tumour Biol; 2015 Aug; 36(8):6037-43. PubMed ID: 25736927
[TBL] [Abstract][Full Text] [Related]
29. MYCN recruits the nuclear exosome complex to RNA polymerase II to prevent transcription-replication conflicts.
Papadopoulos D; Solvie D; Baluapuri A; Endres T; Ha SA; Herold S; Kalb J; Giansanti C; Schülein-Völk C; Ade CP; Schneider C; Gaballa A; Vos S; Fischer U; Dobbelstein M; Wolf E; Eilers M
Mol Cell; 2022 Jan; 82(1):159-176.e12. PubMed ID: 34847357
[TBL] [Abstract][Full Text] [Related]
30. Venetoclax-based Rational Combinations are Effective in Models of
Dalton KM; Krytska K; Lochmann TL; Sano R; Casey C; D'Aulerio A; Khan QA; Crowther GS; Coon C; Cai J; Jacob S; Kurupi R; Hu B; Dozmorov M; Greninger P; Souers AJ; Benes CH; Mossé YP; Faber AC
Mol Cancer Ther; 2021 Aug; 20(8):1400-1411. PubMed ID: 34088831
[TBL] [Abstract][Full Text] [Related]
31. Novel 1p tumour suppressor Dnmt1-associated protein 1 regulates MYCN/ataxia telangiectasia mutated/p53 pathway.
Yamaguchi Y; Takenobu H; Ohira M; Nakazawa A; Yoshida S; Akita N; Shimozato O; Iwama A; Nakagawara A; Kamijo T
Eur J Cancer; 2014 May; 50(8):1555-65. PubMed ID: 24559687
[TBL] [Abstract][Full Text] [Related]
32. Alternative NHEJ pathway proteins as components of MYCN oncogenic activity in human neural crest stem cell differentiation: implications for neuroblastoma initiation.
Newman EA; Chukkapalli S; Bashllari D; Thomas TT; Van Noord RA; Lawlor ER; Hoenerhoff MJ; Opipari AW; Opipari VP
Cell Death Dis; 2017 Dec; 8(12):3208. PubMed ID: 29238067
[TBL] [Abstract][Full Text] [Related]
33. Human neuroblastoma cells with MYCN amplification are selectively resistant to oxidative stress by transcriptionally up-regulating glutamate cysteine ligase.
Veas-Perez de Tudela M; Delgado-Esteban M; Cuende J; Bolaños JP; Almeida A
J Neurochem; 2010 May; 113(4):819-25. PubMed ID: 20180881
[TBL] [Abstract][Full Text] [Related]
34. Targeting MYCN-Driven Transcription By BET-Bromodomain Inhibition.
Henssen A; Althoff K; Odersky A; Beckers A; Koche R; Speleman F; Schäfers S; Bell E; Nortmeyer M; Westermann F; De Preter K; Florin A; Heukamp L; Spruessel A; Astrahanseff K; Lindner S; Sadowski N; Schramm A; Astorgues-Xerri L; Riveiro ME; Eggert A; Cvitkovic E; Schulte JH
Clin Cancer Res; 2016 May; 22(10):2470-81. PubMed ID: 26631615
[TBL] [Abstract][Full Text] [Related]
35. p53 Loss in MYC-Driven Neuroblastoma Leads to Metabolic Adaptations Supporting Radioresistance.
Yogev O; Barker K; Sikka A; Almeida GS; Hallsworth A; Smith LM; Jamin Y; Ruddle R; Koers A; Webber HT; Raynaud FI; Popov S; Jones C; Petrie K; Robinson SP; Keun HC; Chesler L
Cancer Res; 2016 May; 76(10):3025-35. PubMed ID: 27197232
[TBL] [Abstract][Full Text] [Related]
36. Mitotic Dysregulation at Tumor Initiation Creates a Therapeutic Vulnerability to Combination Anti-Mitotic and Pro-Apoptotic Agents for MYCN-Driven Neuroblastoma.
Zhai L; Balachandran A; Larkin R; Seneviratne JA; Chung SA; Lalwani A; Tsubota S; Beck D; Kadomatsu K; Beckers A; Durink K; De Preter K; Speleman F; Haber M; Norris MD; Swarbrick A; Cheung BB; Marshall GM; Carter DR
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958555
[No Abstract] [Full Text] [Related]
37. The MDM2 inhibitor CGM097 combined with the BET inhibitor OTX015 induces cell death and inhibits tumor growth in models of neuroblastoma.
Maser T; Zagorski J; Kelly S; Ostrander A; Goodyke A; Nagulapally A; Bond J; Park Y; Saulnier Sholler G
Cancer Med; 2020 Nov; 9(21):8144-8158. PubMed ID: 33034426
[TBL] [Abstract][Full Text] [Related]
38. KAP1 stabilizes MYCN mRNA and promotes neuroblastoma tumorigenicity by protecting the RNA m
Yang Y; Zhang Y; Chen G; Sun B; Luo F; Gao Y; Feng H; Li Y
J Exp Clin Cancer Res; 2024 May; 43(1):141. PubMed ID: 38745192
[TBL] [Abstract][Full Text] [Related]
39. Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1.
Ying S; Hamdy FC; Helleday T
Cancer Res; 2012 Jun; 72(11):2814-21. PubMed ID: 22447567
[TBL] [Abstract][Full Text] [Related]
40. SGO1 is involved in the DNA damage response in MYCN-amplified neuroblastoma cells.
Murakami-Tonami Y; Ikeda H; Yamagishi R; Inayoshi M; Inagaki S; Kishida S; Komata Y; Jan Koster ; Takeuchi I; Kondo Y; Maeda T; Sekido Y; Murakami H; Kadomatsu K
Sci Rep; 2016 Aug; 6():31615. PubMed ID: 27539729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
